AstraZeneca News

AstraZeneca PLC announced that on 30 May 2012, it purchased for cancellation 700,000 ordinary shares of AstraZeneca PLC at a price of 2603 pence per share.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia The Osaka High Court has reversed a lower court ruling that found the Japanese arm of London-based pharmaceutical company AstraZeneca PLC responsible for deaths caused by side ... (more)

AstraZeneca PLC announced that on 23 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2610 pence per share.

Drug Giants Such as AstraZeneca PLC , GlaxoSmithKline , Sanofi Join Forces With Academia on $285 Million Antibiotic Pact GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat ... (more)

AstraZeneca PLC announced that on 18 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2624 pence per share.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Having suffered a series of late-stage setbacks, AstraZeneca expects to ink several agreements very soon that will boost its pipeline.

Shareholder revolts have claimed the jobs of a handful of Britain's most high profile bosses in the last couple of months, among them David Brennan, the chief executive of drugs giant AstraZeneca .A After six years in the role, Brennan is leaving under a cloud of concern about the drug giant's ability to replenish its product pipeline at a quicker ... (more)

AstraZeneca PLC announced that on 14 May 2012, it purchased for cancellation 525,500 ordinary shares of AstraZeneca PLC at a price of 2665 pence per share.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia AstraZeneca PLC Release: SYMBICORTA Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma WILMINGTON, ... (more)

AstraZeneca opened at 43.44 on Thursday. AstraZeneca has a 1-year low of $40.89 and a 1-year high of $52.54. The company has a market cap of $55.343 billion and a price-to-earnings ratio of 6.66. AstraZeneca last released its earnings data on Thursday, April 26th.

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 313,798 ordinary shares of AstraZeneca PLC at a price of 2709 pence per share on 8 May 2012.

AstraZeneca announced a big acquisition deal on Monday. The U.K. drug maker is planning on buying Ardea Biosciences for $1.26 billion in a deal that will expand Astra's pipeline of new medicines.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia British drug maker GlaxoSmithKline will not be buying smaller rival AstraZeneca .

Targacept's first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program.

AstraZeneca has been backed in to a corner, but it looks as though the drug maker is ready to come out swinging.

NEW HAVEN, CT, USA I May 1, 2012 I Axerion Therapeutics, Inc., a private Connecticut-based biotechnology company, and MedImmune the global biologics arm of AstraZeneca, announced today that they have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's ... (more)